Smith & Nephew (LON:SN) Earns “Outperform” Rating from Royal Bank Of Canada

Smith & Nephew (LON:SN)‘s stock had its “outperform” rating restated by stock analysts at Royal Bank Of Canada in a research report issued to clients and investors on Thursday,Digital Look reports. They presently have a GBX 1,700 target price on the stock. Royal Bank Of Canada’s price objective indicates a potential upside of 37.76% from the stock’s previous close.

A number of other equities research analysts also recently weighed in on the stock. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Smith & Nephew from GBX 1,300 to GBX 1,400 and gave the company a “hold” rating in a research report on Wednesday, August 6th. Citigroup boosted their price objective on shares of Smith & Nephew from GBX 1,450 to GBX 1,600 and gave the company a “buy” rating in a research report on Friday, October 31st. Berenberg Bank upped their target price on Smith & Nephew from GBX 1,100 to GBX 1,300 and gave the stock a “hold” rating in a research note on Thursday, August 7th. Finally, JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Smith & Nephew in a research note on Friday, November 7th. Three analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of GBX 1,487.60.

Smith & Nephew Stock Performance

Shares of Smith & Nephew stock opened at GBX 1,234 on Thursday. The company has a debt-to-equity ratio of 70.22, a quick ratio of 0.84 and a current ratio of 2.51. The company has a 50-day simple moving average of GBX 1,316.44 and a 200-day simple moving average of GBX 1,248.41. The company has a market capitalization of £13.53 billion, a PE ratio of 44.43, a PEG ratio of 0.46 and a beta of 0.62.

Insider Activity

In other Smith & Nephew news, insider Deepak Nath sold 1,240 shares of the business’s stock in a transaction that occurred on Tuesday, November 11th. The stock was sold at an average price of GBX 1,257, for a total value of £15,586.80. 0.19% of the stock is owned by corporate insiders.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.